Display options
Cite
Chakraborty S, Morris MM, Bauer TW, et al. Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Gastrointest Cancer Res. 2014;7(1):15-22
Chakraborty, S., Morris, M. M., Bauer, T. W., Adams, R. B., Stelow, E. B., Petroni, G., & Sanoff, H. K. (2014). Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Gastrointestinal cancer research : GCR, 7(1), 15-22.
Chakraborty, Samhita, et al. "Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer." Gastrointestinal cancer research : GCR vol. 7,1 (2014): 15-22.
Chakraborty S, Morris MM, Bauer TW, Adams RB, Stelow EB, Petroni G, Sanoff HK. Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Gastrointest Cancer Res. 2014 Jan;7(1):15-22. PMID: 24558510; PMCID: PMC3924761.
Copy Download .nbib Format: NLM
Share it on

Gastrointest Cancer Res. 2014 Jan;7(1):15-22.

Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer.

Gastrointestinal cancer research : GCR

Samhita Chakraborty, Monica M Morris, Todd W Bauer, Reid B Adams, Edward B Stelow, Gina Petroni, Hanna K Sanoff

Affiliations

  1. Cancer Center ; Department of Medicine Division of Hematology/Oncology.
  2. Cancer Center ; Department of Radiation Oncology.
  3. Cancer Center ; Department of Surgery Division of Hepatobiliary Surgery.
  4. Cancer Center ; Department of Pathology.
  5. Cancer Center ; Department of Biostatistics University of Virginia Charlottesville, VA.
  6. Cancer Center ; Department of Medicine Division of Hematology/Oncology ; Department of Medicine Division of Hematology/Oncology University of North Carolina Chapel Hill, NC.

PMID: 24558510 PMCID: PMC3924761

Abstract

BACKGROUND: A standard neoadjuvant regimen has not been defined for borderline resectable (BR) pancreatic cancer. This phase II trial was designed to determine the safety of accelerated fraction radiotherapy (AFRT) with capecitabine in patients with BR pancreatic cancer.

METHODS: The patients had newly diagnosed BR adenocarcinoma of the pancreas and normal organ function. Intensity-modulated (n = 11) or 3D conformal (n = 2) radiotherapy was given to a dose of 50 Gy in 2.5-Gy fractions with capecitabine 825 mg/m(2) twice on radiation days. The primary outcome was the frequency of severe treatment-related adverse events (AEs). The study was stopped before planned interim analysis because of 2 severe (grades 4 and 5) gastric ulcerations.

RESULTS: Thirteen patients were enrolled with a median age of 66 years. All patients completed treatment. Seven (54%) experienced grade 3+ treatment-related AEs. Severe gastric ulceration occurred in 2 patients despite receipt of ≥43 Gy to only 1% (2-3 cm(3)) of the stomach. Lymphopenia (n = 7) was the only other severe AE that occurred in >1 patient. In 7 of the 13 patients, disease had progressed outside the pancreas at restaging. Five of the 13 underwent resection, and all had >10% viable tumor. Median progression-free survival (PFS) was 2.4 months (95% CI 1.9-5.9), and median survival was 9.1 months (95% CI 5.9-not reached). Among those who underwent resection, median PFS was 13.0 months (95% CI 4.4-not reached). Median survival was not reached.

CONCLUSIONS: Given the limited efficacy signal and severe gastric ulcerations, we do not recommend this regimen for pancreatic cancer. We also do not recommend the use of high doses per fraction outside a clinical trial.

References

  1. Acta Oncol. 2010 May;49(4):418-22 - PubMed
  2. J Clin Oncol. 1998 Dec;16(12):3843-50 - PubMed
  3. Arch Surg. 1985 Aug;120(8):899-903 - PubMed
  4. JAMA. 2010 Sep 8;304(10):1073-81 - PubMed
  5. JAMA. 2012 Apr 18;307(15):1611-20 - PubMed
  6. J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 - PubMed
  7. J Surg Oncol. 2010 Jun 1;101(7):587-92 - PubMed
  8. Neoplasia. 2013 Feb;15(2):143-55 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e469-74 - PubMed
  10. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S101-7 - PubMed
  12. J Surg Oncol. 2011 Aug 1;104(2):155-61 - PubMed
  13. J Clin Oncol. 2012 Aug 1;30(22):2788-97 - PubMed
  14. JAMA. 2007 Jan 17;297(3):267-77 - PubMed
  15. Radiother Oncol. 2005 Jul;76(1):48-53 - PubMed
  16. BMC Cancer. 2012 May 29;12:199 - PubMed
  17. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 - PubMed
  18. Ann Surg Oncol. 2009 Jul;16(7):1751-6 - PubMed
  19. Arch Surg. 1992 Nov;127(11):1335-9 - PubMed
  20. J Clin Oncol. 2002 May 15;20(10):2537-44 - PubMed
  21. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71 - PubMed
  22. Med Care. 1996 Jan;34(1):73-84 - PubMed
  23. J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8 - PubMed
  24. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 - PubMed
  25. Radiother Oncol. 1988 Sep;13(1):61-8 - PubMed
  26. Surgery. 2011 Sep;150(3):466-73 - PubMed
  27. J Clin Oncol. 2008 Jul 20;26(21):3496-502 - PubMed
  28. Surgery. 2012 Nov;152(5):851-62 - PubMed
  29. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):678-86 - PubMed
  30. Acta Radiol Ther Phys Biol. 1966 Aug;4(4):289-97 - PubMed
  31. J Clin Oncol. 2008 Jul 20;26(21):3487-95 - PubMed
  32. Ann Surg Oncol. 2011 Mar;18(3):619-27 - PubMed
  33. Cancer. 2013 Jan 15;119(2):277-84 - PubMed

Publication Types

Grant support